Search

Your search keyword '"Bouchaab, H."' showing total 5 results
Start Over Author "Bouchaab, H." Topic medical oncology
5 results on '"Bouchaab, H."'

1. [Oncology: what's new in 2023].

Author

Jankovic J, Abdelhamid K, Berthold D, Desbaillets N, Bouchaab H, Dei Tos G, Demicheli R, Diciolla A, Digklia A, Ferraro DA, Florez L, Galli-Vareia I, Hottinger A, Latifyan S, Liapi A, Mederos N, Giacomuzzi Moore B, Sakr R, Stamatiou A, Wagner AD, Peters S, Sarivalasis A, Vanniere F, Zaman K, and Stravodimou A

Subjects
Humans, Quality of Life, Medical Oncology
Abstract

The oncology field continues its remarkable evolution over the years, with promising advances leading to innovative and individualized treatments. The development of new molecules, the identification of new therapeutic targets and the search for new sequences or combinations promise to revolutionize cancer treatments and contribute to improving survival rates, patients' quality of life and to open new perspective in oncology research. In this article, the newest data released in 2023 are reviewed., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.

Published
2024
Full Text
View/download PDF

2. [Oncology: what's new in 2022].

Author

Nguyen-Ngoc T, Abdelhamid K, Degrauwe N, Galland S, Serena A, Christofis M, Mederos N, Bouchaab H, Diciolla A, Dris N, Orcurto A, Perrinjaquet C, Schnetz M, Latifyan S, Wetterwald L, Herrera Gómez RG, Cristina V, Sarivalasis A, Michielin O, Berthold D, Digklia A, Wagner AD, Zaman K, Peters S, and Stravodimou A

Subjects
Humans, Immunotherapy, Neoadjuvant Therapy, Medical Oncology, Lung Neoplasms therapy
Abstract

The past year has brought several innovations in medical oncology, opening up promising new options for many solid tumors, both localized and metastatic. Immunotherapy, a real spearhead of emerging therapies in metastatic diseases, is seeing its use extend to adjuvant and neoadjuvant modalities, particularly in colon and lung cancers. 2022 also sees a great deal of focus on targeted therapies, as well as on antibody-drug conjugates, which creates new standards in both breast and lung cancers. Here we present the major advances in solid tumors., Competing Interests: Les autres auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.

Published
2023
Full Text
View/download PDF

3. [Oncology, what's new in 2018].

Author

Latifyan S, Kakourou A, Ozdemir B, Zaman K, Vernadou A, Berthold D, Abdelhamid K, Bouchaab H, Peters S, Montemurro M, Aedo V, Michielin O, Zimmermann S, and Stravodimou A

Subjects
Combined Modality Therapy, Humans, Immunotherapy, Adoptive, Immunotherapy, Medical Oncology trends, Neoplasms therapy
Abstract

The year 2018 has been incredibly prolific regarding novelties. Several studies have given impressive results and offer new anticancer perspectives. Immunotherapy is gaining more and more place defining a new standard of care for different types of cancer. In parallel with a new approach combining immunotherapy and chemotherapy that is emerging, new forms of adoptive immunotherapy are on the path of approval by regulatory authorities. At the decision-making level, a large somatic genetic analysis is becoming dominant, whereas the addition of more specific biomarkers is still needed regarding immunotherapy. This article aims to summarize the significant new developments in oncology for 2018 concerning the five most common cancers and adoptive cellular immunotherapy., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.

Published
2019

4. Oncologie [2020 oncology update]

Author

Dei Tos, G., Galli Vareia, I., Huber, A., Wolf, B., Diciolla, A., Herrera Gomez, R.G., Wagner, D., Digklia, A., Bouchaab, H., Cristina, V., Stravodimou, A., Zaman, K., Sarivalasis, A., Berthold, D., Peters, S., Perrinjaquet, C., Kloepper, J., and Jankovic, J.

Subjects
COVID-19, Humans, Medical Oncology, Neoplasms, Pandemics, Quality of Life, SARS-CoV-2
Abstract

The COVID-19 pandemic that has swept around the world in early 2020 has changed our daily practice and habits. Fortunately, however, 2020 also brings its share of new approaches and therapeutic combinations as well as new therapies. These advances are improving the outcomes and quality of life of our patients across the spectrum of oncological diseases. This article summarises the latest oncological advances and novelties for 2020 in the following tumor entities : lung, breast, digestive, gynecological, urological and ENT.

Published
2021

5. ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

Author

Passaro, A., Addeo, A., Von Garnier, C., Blackhall, F., Planchard, D., Felip, E., Dziadziuszko, R., de Marinis, F., Reck, M., Bouchaab, H., and Peters, S.

Subjects
Ambulatory Care, Betacoronavirus, Carcinoma, Non-Small-Cell Lung/pathology, Carcinoma, Non-Small-Cell Lung/therapy, Chemoradiotherapy, Coronavirus Infections/epidemiology, Delivery of Health Care/methods, Humans, Lung Neoplasms/pathology, Lung Neoplasms/therapy, Medical Oncology, Neoplasm Staging, Pandemics, Pneumonectomy, Pneumonia, Viral/epidemiology, Practice Guidelines as Topic, Radiation Oncology, Radiosurgery, Small Cell Lung Carcinoma/pathology, Small Cell Lung Carcinoma/therapy, Surgical Oncology, Telemedicine, Time-to-Treatment, Tomography, X-Ray Computed, Triage, COVID19, SARS-CoV-2, lung cancer
Abstract

The COVID-19 pandemic, characterised by a fast and global spread during the first months of 2020, has prompted the development of a structured set of recommendations for cancer care management, to maintain the highest possible standards. Within this framework, it is crucial to ensure no disruption to essential oncological services and guarantee the optimal care.This is a structured proposal for the management of lung cancer, comprising three levels of priorities, namely: tier 1 (high priority), tier 2 (medium priority) and tier 3 (low priority)-defined according to the criteria of the Cancer Care Ontario, Huntsman Cancer Institute and Magnitude of Clinical Benefit Scale.The manuscript emphasises the impact of the COVID-19 pandemic on lung cancer care and reconsiders all steps from diagnosis, staging and treatment.These recommendations should, therefore, serve as guidance for prioritising the different aspects of cancer care to mitigate the possible negative impact of the COVID-19 pandemic on the management of our patients.As the situation is rapidly evolving, practical actions are required to guarantee the best patients' treatment while protecting and respecting their rights, safety and well-being. In this environment, cancer practitioners have great responsibilities: provide timely, appropriate, compassionate and justified cancer care, while protecting themselves and their patients from being infected with COVID-19. In case of shortages, resources must be distributed fairly. Consequently, the following recommendations can be applied with significant nuances, depending on the time and location for their use, considering variable constraints imposed to the health systems. An exceptional flexibility is required from cancer caregivers.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results